NWQ Investment Management Company LLC lifted its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 24.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,204,186 shares of the company’s stock after purchasing an additional 236,685 shares during the quarter. NWQ Investment Management Company LLC owned about 0.12% of Teva Pharmaceutical Industries worth $22,819,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Franklin Resources Inc. boosted its stake in Teva Pharmaceutical Industries by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock worth $1,506,309,000 after buying an additional 6,009,897 shares during the period. Two Sigma Advisers LP purchased a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $118,487,000. Schroder Investment Management Group boosted its stake in Teva Pharmaceutical Industries by 22.7% during the third quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock worth $106,290,000 after buying an additional 1,147,683 shares during the period. Macquarie Group Ltd. boosted its stake in Teva Pharmaceutical Industries by 350.3% during the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after buying an additional 3,429,448 shares during the period. Finally, OppenheimerFunds Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $69,418,000. 58.22% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have weighed in on TEVA shares. Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, January 11th. Morgan Stanley raised shares of Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 target price for the company in a research note on Friday, December 15th. Royal Bank of Canada set a $11.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “sell” rating in a research note on Wednesday, November 29th. Cantor Fitzgerald set a $10.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, December 14th. Finally, Susquehanna Bancshares reaffirmed a “positive” rating and set a $24.00 target price (up previously from $22.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, January 25th. Ten analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have issued a buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and an average target price of $20.81.
Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) opened at $19.32 on Wednesday. The firm has a market cap of $19,829.10, a P/E ratio of 5.03, a P/E/G ratio of 1.69 and a beta of 0.65. Teva Pharmaceutical Industries Ltd has a 1-year low of $10.85 and a 1-year high of $34.51. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.14. The firm had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm’s revenue was down 15.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.38 earnings per share. equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.31 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/03/14/nwq-investment-management-company-llc-has-22-82-million-position-in-teva-pharmaceutical-industries-ltd-teva.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.